DE60023128D1 - Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen - Google Patents

Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen

Info

Publication number
DE60023128D1
DE60023128D1 DE60023128T DE60023128T DE60023128D1 DE 60023128 D1 DE60023128 D1 DE 60023128D1 DE 60023128 T DE60023128 T DE 60023128T DE 60023128 T DE60023128 T DE 60023128T DE 60023128 D1 DE60023128 D1 DE 60023128D1
Authority
DE
Germany
Prior art keywords
fatibility
pyrazolecarboxamide
diseases
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60023128T
Other languages
English (en)
Other versions
DE60023128T2 (de
Inventor
P Kordik
W Lovenberg
B Reitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Application granted granted Critical
Publication of DE60023128D1 publication Critical patent/DE60023128D1/de
Publication of DE60023128T2 publication Critical patent/DE60023128T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
DE60023128T 1999-05-12 2000-05-02 Pyrazolcarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen Expired - Fee Related DE60023128T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13384299P 1999-05-12 1999-05-12
US133842P 1999-05-12
PCT/US2000/011903 WO2000069849A1 (en) 1999-05-12 2000-05-02 Pyrazole carboxamides useful for the treatment of obesity and other disorders

Publications (2)

Publication Number Publication Date
DE60023128D1 true DE60023128D1 (de) 2006-02-23
DE60023128T2 DE60023128T2 (de) 2006-07-06

Family

ID=22460538

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60023128T Expired - Fee Related DE60023128T2 (de) 1999-05-12 2000-05-02 Pyrazolcarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen

Country Status (8)

Country Link
US (2) US6291476B1 (de)
EP (1) EP1177188B1 (de)
AR (1) AR023957A1 (de)
AT (1) ATE306481T1 (de)
AU (1) AU778393B2 (de)
CA (1) CA2373510A1 (de)
DE (1) DE60023128T2 (de)
WO (1) WO2000069849A1 (de)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
SE0004462D0 (sv) * 2000-12-04 2000-12-04 Pharmacia Ab Novel method and use
AU2002221222A1 (en) * 2000-12-04 2002-06-18 Biovitrum Ab Novel method and use
GB0121941D0 (en) 2001-09-11 2001-10-31 Astrazeneca Ab Chemical compounds
GT200200188A (es) * 2001-09-24 2003-06-25 Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad
WO2003037332A1 (en) * 2001-10-12 2003-05-08 Bayer Pharmaceuticals Corporation Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
AU2003245773A1 (en) 2002-02-15 2003-09-04 Glaxo Group Limited Vanilloid receptor modulators
US7074805B2 (en) * 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
AU2003251739A1 (en) * 2002-07-02 2004-01-23 Schering Corporation New neuropeptide y y5 receptor antagonists
EP1433788A1 (de) * 2002-12-23 2004-06-30 Aventis Pharma Deutschland GmbH Pyrazol-Derivate als Faktor Xa Inhibitoren
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
ES2337254T3 (es) 2003-02-14 2010-04-22 Glaxo Group Limited Derivados de carboxamida.
CA2525325A1 (en) * 2003-05-01 2004-11-18 Abbott Laboratories Pyrazole-amides and sulfonamides as sodium channel modulators
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
US20050004133A1 (en) * 2003-06-05 2005-01-06 Makings Lewis R. Modulators of VR1 receptor
US7015233B2 (en) * 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
WO2005011677A1 (en) * 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases
US20050113576A1 (en) * 2003-08-05 2005-05-26 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
WO2005028438A1 (ja) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
TW200533657A (en) * 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
WO2006032851A1 (en) * 2004-09-20 2006-03-30 Biolipox Ab Pyrazole compounds useful in the treatment of inflammation
CN101094689B (zh) 2004-11-01 2013-06-12 安米林药品有限责任公司 治疗肥胖以及肥胖相关疾病和病症的方法
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
EP1853610A1 (de) * 2005-03-03 2007-11-14 Sirtris Pharmaceuticals, Inc. N-phenyl-benzamid-derivate als sirtuin-modulatoren
US7745451B2 (en) 2005-05-04 2010-06-29 Renovis, Inc. Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and dysfunctions
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US8138206B2 (en) 2005-05-30 2012-03-20 Msd. K.K. Piperidine derivative
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
EP1743890A1 (de) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. 4,5-Dihydro-1H-Pyrazol-Derivative, Verfahren zur Herstellung und ihre Verwendung als Medikamente.
EP1743892A1 (de) * 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituierte Pyrazolin Verbindungen, deren Herstellung und Verwendung als Medikament
EP1757587A1 (de) * 2005-07-15 2007-02-28 Laboratorios Del Dr. Esteve, S.A. Substituierte Pyrazolinderivate, ihre Herstellung und Verwendung als Arzneimittel
US7897589B2 (en) * 2005-07-15 2011-03-01 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
US8093401B2 (en) * 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) * 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) * 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7345178B2 (en) 2005-08-04 2008-03-18 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
JPWO2007018248A1 (ja) 2005-08-10 2009-02-19 萬有製薬株式会社 ピリドン化合物
EP1922336B1 (de) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybridpolypeptide mit auswählbaren eigenschaften
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
DE602006017712D1 (de) 2005-08-24 2010-12-02 Banyu Pharma Co Ltd Phenylpyridonderivat
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
CA2624030A1 (en) 2005-09-29 2007-04-12 Tianying Jian Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
TW200800911A (en) * 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
EP2332526A3 (de) 2005-10-21 2011-10-12 Novartis AG Kombination eines Renin-Inhibitors mit einem anti-dyslipidämischen Wirkstoff oder einem Wirkstoff gegen Adipositas
CA2627139A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
NZ567605A (en) * 2005-10-31 2010-07-30 Biolipox Ab Triazole compounds as lipoxygenase inhibitors
TW200732320A (en) * 2005-10-31 2007-09-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
US20090088463A1 (en) * 2005-11-01 2009-04-02 Benjamin Pelcman Pyrazoles Useful in the Treatment of Inflammation
EP1953165B1 (de) 2005-11-10 2012-02-01 Msd K.K. Aza-substituierte spiroderivate
NZ574533A (en) 2006-08-01 2011-05-27 Glaxo Group Ltd Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
US7767705B2 (en) * 2006-08-25 2010-08-03 Abbott Laboratories Compounds that inhibit TRPV1 and uses thereof
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
EP2072519A4 (de) 2006-09-28 2009-10-21 Banyu Pharma Co Ltd Diarylketiminderivat
WO2008079683A2 (en) 2006-12-20 2008-07-03 Abbott Laboratories N- (5, 6, 7, 8-tetrahydronaphthalen-1-yl) urea derivatives and related compounds as trpv1 vanilloid receptor antagonists for the treatment of pain
EP2136639B1 (de) 2007-04-02 2016-03-09 Evotec AG Pyrid-2-yl-anellierte heterocyclische verbindungen, und ihre zusammensetzungen und verwendungen
WO2008120653A1 (ja) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. インドールジオン誘導体
PL2139334T3 (pl) 2007-04-17 2013-11-29 Evotec Ag Skondensowane związki heterocykliczne 2-cyjanofenylu i ich kompozycje i zastosowania
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2998314B1 (de) 2007-06-04 2020-01-22 Bausch Health Ireland Limited Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
CL2008001822A1 (es) * 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
CA2691507C (en) * 2007-07-19 2016-06-21 H. Lundbeck A/S 5-membered heterocyclic amides and related compounds
EP2173717B9 (de) 2007-07-27 2013-06-26 Bristol-Myers Squibb Company Neuartige glucokinase-aktivatoren und verfahren zu ihrer verwendung
BRPI0819093A2 (pt) * 2007-11-01 2017-05-02 Sirtris Pharmaceuticals Inc compostos moduladores de sirtuína
BRPI0820377A2 (pt) * 2007-11-08 2015-05-19 Sirtris Pharmaceutical Inc Tiazolopiridinas solubilizadas
EP2262766B1 (de) 2008-02-29 2015-11-11 Evotec AG Amidverbindungen, ihre zusammensetzungen und ihre verwendung
EP2264026A4 (de) 2008-03-06 2012-03-28 Msd Kk Alkylaminopyridinderivate
MX2010010262A (es) * 2008-03-20 2010-12-06 Abbott Lab Metodos para la elaboracion de agentes para el sistema nervioso central que son antagonistas del trpv1.
CN101981025A (zh) 2008-03-28 2011-02-23 万有制药株式会社 具有黑色素浓缩激素受体拮抗作用的二芳基甲基酰胺衍生物
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2301936A1 (de) 2008-06-19 2011-03-30 Banyu Pharmaceutical Co., Ltd. Spirodiamin-diarylketoximid-derivat
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2151234A1 (de) * 2008-07-28 2010-02-10 Laboratorios Del. Dr. Esteve, S.A. Pharmazeutische Formulierung mit einer CB1-Rezeptorverbindung in einer festen Lösung und/oder festen Dispersion
US20110124674A1 (en) 2008-07-30 2011-05-26 Hiroyuki Kishino 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
CN102264228A (zh) 2008-10-22 2011-11-30 默沙东公司 用于抗糖尿病药的新的环状苯并咪唑衍生物
PE20110852A1 (es) 2008-10-30 2011-11-25 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
EP2379562A1 (de) 2008-12-16 2011-10-26 Schering Corporation Bicyclische pyranonderivate als agonisten am nicotinsäurerezeptor
EP2379547A1 (de) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidinderivate und verfahren zu deren anwendung
US8343997B2 (en) 2008-12-19 2013-01-01 Sirtris Pharmaceuticals, Inc. Thiazolopyridine sirtuin modulating compounds
US8946231B2 (en) 2009-03-23 2015-02-03 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN103476258B (zh) 2011-02-25 2017-04-26 默沙东公司 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
EP2970119B1 (de) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Neuartige indolderivate als antidiabetika
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9708272B2 (en) 2014-08-29 2017-07-18 Tes Pharma S.R.L. Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
JP6896715B2 (ja) 2015-09-30 2021-06-30 マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ヴィッセンシャフテン エーファウ −ジェネラルフェルヴァルトゥング セピアプテリン還元酵素としてのヘテロアリール誘導体
RS60825B1 (sr) 2016-03-17 2020-10-30 Hoffmann La Roche Aktivnost derivata 5-etiol-4-metil-pirazol-3-karboksamida kao agonista taar-a
RU2019114228A (ru) 2016-10-14 2020-11-16 Тес Фарма С.Р.Л. ИНГИБИТОРЫ ДЕКАРБОКСИЛАЗЫ ПОЛУАЛЬДЕГИДА α-АМИНО-β-КАРБОКСИМУКОНОВОЙ КИСЛОТЫ
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (de) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. Antidiabetische spirochromanverbindungen
KR20210111248A (ko) 2018-11-20 2021-09-10 테스 파마 에스.알.엘. α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제
TW202045476A (zh) 2019-02-13 2020-12-16 美商默沙東藥廠 5-烷基吡咯啶食慾素受體促效劑
EP4010314B1 (de) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl-pyrrolidin- und piperidinorexinrezeptor-agonisten
WO2021032935A1 (en) * 2019-08-21 2021-02-25 Kalvista Pharmaceuticals Limited Enzyme inhibitors
WO2021046515A1 (en) * 2019-09-06 2021-03-11 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
CN115605463A (zh) 2019-09-27 2023-01-13 德州大学系统董事会（Us） 用于治疗疾病的受体相互作用蛋白激酶i的抑制剂
BR112022010082A2 (pt) 2019-11-26 2022-08-30 Univ Texas Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica
WO2022040070A1 (en) 2020-08-18 2022-02-24 Merck Sharp & Dohme Corp. Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0041322A1 (de) * 1980-05-30 1981-12-09 Beecham Group Plc m-Pyrazolylamidotetramisol-Derivate, Verfahren zur Herstellung dieser Verbindungen, sie enthaltende Zusammensetzungen sowie ihre Verwendung bei der Behandlung der Helminthiasis
JPS6425763A (en) * 1987-04-24 1989-01-27 Mitsubishi Chem Ind Pyrazoles and insecticide and acaricide containing said pyrazoles as active ingredient
JPH04247081A (ja) * 1991-02-01 1992-09-03 Takeda Chem Ind Ltd ５員複素環酸アミド類
PL321136A1 (en) 1994-11-07 1997-11-24 Pfizer Some substituted derivatives of bencylamine as a new class of specific ligands of neuropeptide y1
US5900415A (en) 1994-11-07 1999-05-04 Pfizer Inc. Certain substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5668151A (en) 1995-06-07 1997-09-16 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: piperidine derivatives
EP0945438B1 (de) 1996-12-12 2003-03-05 Banyu Pharmaceutical Co., Ltd. Pyrazolderivate
EP0945439B1 (de) 1996-12-13 2003-03-19 Banyu Pharmaceutical Co., Ltd. Aminopyrazolderivate
CA2274594C (en) 1996-12-16 2006-10-10 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
WO1998041508A1 (en) * 1997-03-18 1998-09-24 Smithkline Beecham Plc Substituted isoquinoline derivatives and their use as anticonvulsants
ZA985247B (en) * 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.

Also Published As

Publication number Publication date
US6291476B1 (en) 2001-09-18
AR023957A1 (es) 2002-09-04
ATE306481T1 (de) 2005-10-15
WO2000069849A1 (en) 2000-11-23
EP1177188B1 (de) 2005-10-12
AU778393B2 (en) 2004-12-02
AU4690600A (en) 2000-12-05
DE60023128T2 (de) 2006-07-06
EP1177188A1 (de) 2002-02-06
CA2373510A1 (en) 2000-11-23
US6511998B2 (en) 2003-01-28
US20020058816A1 (en) 2002-05-16

Similar Documents

Publication Publication Date Title
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE308997T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
ATE319453T1 (de) Reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
DE60108080D1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69918687D1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
DE69929996D1 (de) Pharmazeutisches mittel zur behandlung von diabetes
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
ATE381347T1 (de) Kombinationen von ezetimibe und aspirin zur behandlung von kardiovaskulären erkrankungen
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60027290D1 (de) Skleraprothese zur behandlung der weitsichtigkeit und anderer augenkrankheiten
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
ATE299371T1 (de) Antikonvulsiva zur behandlung von autismus
ATE314064T1 (de) L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
DE60005685D1 (de) Oxazinocarbazole zur behandlung von cns-erkrankungen
ATE285764T1 (de) Rivastigmine zur behandlung von augenerkrankungen
ATE443060T1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
DE60036723D1 (de) Mesoprogestine zur behandlung und vorbeugung von hormonabhängigen gutartigen gynekologischen störungen
DE60107900D1 (de) Pharmazeutische Zusammensetzung und Nahrungsmittel zur Behandlung von Gehirnödem

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: BOEHMERT & BOEHMERT, 28209 BREMEN

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee